MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
Agreement On Tasigna Generics Represents First Such Deal For A Cancer Medicine
The Medicines Patent Pool has struck a milestone voluntary licensing deal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”
